Back to Agenda
Does Diversity Matter in Clinical Trials?
Session Chair(s)
Joe V. Selby, DrMed, MPH
Founding Executive Director
Patient-Centered Outcomes Research Institute (PCORI), United States
As we seek to ensure that the right medicines are available for the right patients at the right time, the representation of appropriate population groups in clinical trials is increasingly important. In this DIAmond session, a multi-stakeholder panel takes a 360 degree view of the issue of diversity in today’s clinical trials. What constitutes a diverse, representative population for a clinical trial? Does the focus on personalized medicine have an impact on the context of diversity? What is the status of including more diverse populations in clinical trials, and is progress consistent for racial/ethnic minority, female, and elderly populations? What is the outlook for current efforts and initiatives to address these issues?
Learning Objective : Describe the current status of clinical trials in the US in terms of appropriate diversity among study participants; Discuss the factors that determine appropriate diversity within clinical study populations; Identify and discuss at least two current initiatives that address the need to diversify the make-up of clinical study populations.
Speaker(s)
Panelist
John Whyte, DrMed, MD, MPH
WebMD, United States
Chief Medical Officer
Panelist
Sam S. Oh, PhD, MPH
UCSF School of Medicine, United States
Director of Epidemiology, Asthma Collaboratory
Panelist
Karen Correa, PhD
Takeda, United States
Vice President, Head of Global Clinical Operations
Panelist
Nikos Dedes
European AIDS Treatment Group (EATG), Greece
Representative, European AIDS Treatment Group (EATG)
Panelist
Regina Greer-Smith, MPH
Healthcare Research Associates LLC, United States
Founder/Owner The S.T.A.R. Initiative
Have an account?